Baird raised the firm’s price target on Taysha Gene Therapies (TSHA) to $12 from $7 and keeps an Outperform rating on the shares. The firm said they are positive on the finalization of its pivotal TSHA-102 study and regulatory alignment.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
- Taysha Gene Therapies price target raised to $12 from $7 at Baird
- Berkshire to acquire OxyChem, OpenAI reaches $500B valuation: Morning Buzz
- Promising Prospects for Taysha Gene Therapies: Buy Rating Backed by Strategic Advancements and Regulatory Endorsements
- Needham ups Taysha target on ‘derisking’ TSHA-102 news